Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium.
DeRusso PA, Ye W, Shepherd R, Haber BA, Shneider BL, Whitington PF, Schwarz KB, Bezerra JA, Rosenthal P, Karpen S, Squires RH, Magee JC, Robuck PR, Sokol RJ; Biliary Atresia Research Consortium. DeRusso PA, et al. Among authors: haber ba. Hepatology. 2007 Nov;46(5):1632-8. doi: 10.1002/hep.21923. Hepatology. 2007. PMID: 17929308 Free PMC article.
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network. Schwarz KB, et al. Among authors: haber ba. Gastroenterology. 2011 Feb;140(2):450-458.e1. doi: 10.1053/j.gastro.2010.10.047. Epub 2010 Oct 28. Gastroenterology. 2011. PMID: 21036173 Free PMC article. Clinical Trial.
Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.
Kelly DA, Haber B, González-Peralta RP, Murray KF, Jonas MM, Molleston JP, Narkewicz MR, Sinatra FR, Lang T, Lachaux A, Wirth S, Shelton M, Te HS, Pollack H, Deng W, Noviello S, Albrecht JK. Kelly DA, et al. J Viral Hepat. 2012 Apr;19(4):263-70. doi: 10.1111/j.1365-2893.2011.01544.x. Epub 2011 Nov 17. J Viral Hepat. 2012. PMID: 22404724
Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.
Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network. Molleston JP, et al. Among authors: haber ba. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):304-10. doi: 10.1097/MPG.0b013e3182774cae. J Pediatr Gastroenterol Nutr. 2013. PMID: 23439301 Free PMC article. Clinical Trial.
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Gonzalez-Peralta RP, Wirth S, Squires RH, Mutschler F, Lang T, Pawlowska M, Sluzewski W, Majda-Stanislawska E, Fischler B, Balistreri WF, Jonas MM, Blondet N, Rosenthal P, Alkhouri N, Romero R, Grandhi A, Castronuovo P, Caro L, Du L, Rosenbloom DIS, Haber BA. Gonzalez-Peralta RP, et al. Among authors: haber ba. Hepatol Commun. 2023 Feb 14;7(3):e0031. doi: 10.1097/HC9.0000000000000031. eCollection 2023 Mar 1. Hepatol Commun. 2023. PMID: 36790337 Free PMC article.
To treat or not to treat: that is the question.
Haber BA. Haber BA. J Pediatr Gastroenterol Nutr. 2004 Jul;39(1):103-4. doi: 10.1097/00005176-200407000-00022. J Pediatr Gastroenterol Nutr. 2004. PMID: 15187792 No abstract available.
58 results